Amicus Therapeutics, Inc. $FOLD Shares Bought by Allianz Asset Management GmbH

Allianz Asset Management GmbH grew its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 4.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 387,776 shares of the biopharmaceutical company’s stock after acquiring an additional 16,367 shares during the quarter. Allianz Asset Management GmbH owned about 0.13% of Amicus Therapeutics worth $2,222,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of FOLD. Nuveen LLC acquired a new position in shares of Amicus Therapeutics during the 1st quarter valued at about $28,741,000. Assenagon Asset Management S.A. increased its stake in shares of Amicus Therapeutics by 641.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 3,533,854 shares of the biopharmaceutical company’s stock valued at $20,249,000 after acquiring an additional 3,057,072 shares during the last quarter. Millennium Management LLC increased its position in Amicus Therapeutics by 635.1% during the 1st quarter. Millennium Management LLC now owns 3,359,389 shares of the biopharmaceutical company’s stock worth $27,413,000 after purchasing an additional 2,902,375 shares in the last quarter. Redmile Group LLC increased its position in Amicus Therapeutics by 35.1% during the 1st quarter. Redmile Group LLC now owns 9,533,669 shares of the biopharmaceutical company’s stock worth $77,795,000 after purchasing an additional 2,478,779 shares in the last quarter. Finally, Vestal Point Capital LP increased its position in Amicus Therapeutics by 27.6% during the 1st quarter. Vestal Point Capital LP now owns 4,275,000 shares of the biopharmaceutical company’s stock worth $34,884,000 after purchasing an additional 925,000 shares in the last quarter.

Amicus Therapeutics Stock Up 2.0%

Shares of NASDAQ:FOLD opened at $8.67 on Friday. The company has a quick ratio of 2.29, a current ratio of 3.21 and a debt-to-equity ratio of 1.92. Amicus Therapeutics, Inc. has a 52-week low of $5.51 and a 52-week high of $12.65. The company has a 50 day moving average of $8.02 and a two-hundred day moving average of $6.93. The company has a market capitalization of $2.67 billion, a price-to-earnings ratio of -72.24 and a beta of 0.56.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on FOLD shares. Morgan Stanley raised shares of Amicus Therapeutics from an “equal weight” rating to an “overweight” rating in a research report on Thursday, July 17th. Needham & Company LLC raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research report on Thursday, September 18th. Zacks Research raised shares of Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 6th. Wall Street Zen downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, October 18th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Amicus Therapeutics in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Amicus Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $15.88.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.